Implicit Bioscience
Implicit Bioscience is developing groundbreaking immunotherapy treatments for serious, often fatal, diseases 👉 #IC14
Implicit Bioscience is developing groundbreaking immunotherapy treatments for serious, often fatal, diseases 👉 #IC14
Implicit Bioscience Analysis
Name: Implicit Bioscience
Slogan: Implicit Bioscience is developing groundbreaking immunotherapy treatments for serious, often fatal, diseases 👉 #IC14
Description: Implicit Bioscience, founded in 2004, is an unlisted public company based in Brisbane and Seattle. Led by biopharma veterans including Prof. Peter Andrews AO and Prof. Ian Frazer AC FRS, the company aims to revolutionize treatment for severe, life-threatening diseases lacking effective therapies. Implicit Bioscience holds global rights to IC14, a biologic monoclonal antibody drug targeting CD14, a key regulator of immune response and brain cell protection. The company focuses on leveraging immunoneurology to address neurodegenerative and neurotraumatic diseases, particularly MND/ALS, by combating damaging inflammation.
Industries: Biotechnology, Health Care
Last Investment: $65.55K Venture Round investment on August 28, 2020
Investors: Not disclosed
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | $65.55K | - | 28 Aug 2020 | |
| Venture Round | $367.23K | - | 13 Sep 2019 | |
| Venture Round | $210.07K | - | 15 Nov 2016 | |
| Pre Seed Round | $50.80K | - | 16 Nov 2015 | |
| Pre Seed Round | Unknown | - | 19 Dec 2013 |
No recent news or press coverage available for Implicit Bioscience.
We care about your data, and we'd love to use cookies make your experience better.
-logo.jpg){kind=logo}